Myriad Genetics INC 8-K filings

Myriad Genetics reported a 11% year-over-year revenue decrease for Q2 2026, driven by lower average revenue per test and volume challenges in certain segments, while launching new initiatives for efficiency and scalability.

Myriad Genetics held its 2026 Annual Meeting, where stockholders approved amendments to equity incentive plans, increasing share availability for employees and directors.

Myriad Genetics reported first quarter 2026 revenue of $200.4 million, a 2% increase year-over-year, driven by growth in Cancer Care Continuum and Mental Health, while reiterating full-year 2026 financial guidance.

Myriad Genetics reported Q4 2025 financial results, showing revenue consistent with the prior year and growth in key test volumes, while reiterating 2026 financial guidance.

Myriad Genetics announced select unaudited preliminary results for the fourth quarter and full year 2025 and provided full year 2026 financial guidance.

Myriad Genetics reported third quarter 2025 financial results, with revenue of $205.7 million, and reaffirmed its full-year 2025 financial guidance.

Myriad Genetics announced third quarter 2025 financial results, reporting stable revenue excluding headwinds and reaffirming its full-year 2025 financial guidance.

Myriad Genetics, Inc. entered into a Separation Agreement with former Chief Financial Officer Scott J. Leffler, detailing severance and equity arrangements.

Myriad Genetics announced the resignation of its Chief Accounting Officer, Natalie Munk, and the appointment of CFO Benjamin R. Wheeler to assume the additional role.

Myriad Genetics, Inc. announced the departure of Scott J. Leffler as Chief Financial Officer and the appointment of Ben R. Wheeler to the role, effective August 16, 2025.

Myriad Genetics reported a significant net loss in Q2 2025 due to impairment charges, while raising full-year revenue guidance and securing a new credit facility.

Myriad Genetics, a leader in molecular diagnostic testing, has closed a new five-year senior secured term loan credit facility of up to $200 million with OrbiMed to support its growth strategy and refinance existing debt.

Myriad Genetics, Inc. announced that its stockholders approved an amendment to the 2017 Equity Incentive Plan, increasing the share pool by 6.5 million shares, and re-elected three directors at its 2025 Annual Meeting.

Myriad Genetics' Q1 2025 revenue declined 3% year-over-year, but the company updated its full-year financial guidance to reflect these results and the current business outlook.

Myriad Genetics announced the appointment of Samraat S. Raha as CEO, succeeding Paul J. Diaz, and Mark S. Verratti as COO, effective April 30, 2025, alongside Q4 and full-year 2024 financial results.

Myriad Genetics released preliminary unaudited financial results for Q4 and full year 2024, showing revenue growth and provided financial guidance for 2025.

Myriad Genetics has appointed Mark S. Davis to its Board of Directors, increasing the board size to nine members and adding his financial expertise to the Audit and Finance Committee.

Myriad Genetics has received court approval to settle a shareholder derivative lawsuit, which includes a $950,000 payment for attorneys' fees and the implementation of corporate governance reforms.

Myriad Genetics announced an 11% year-over-year revenue increase for the third quarter of 2024, driven by growth in pharmacogenomics and prenatal testing, while also updating its full-year financial guidance.

Myriad Genetics expects third quarter 2024 revenue between $210 million and $212 million and reaffirms its full-year 2024 revenue guidance of $835 million to $845 million.

Myriad Genetics has halted the second part of its economic utility study on GeneSight testing due to significant disparities found in the control group, rendering the comparison unreliable.

Myriad Genetics announced a 15% year-over-year revenue increase in the second quarter of 2024, driven by strong performance across its portfolio, and raised its full-year financial guidance.

Myriad Genetics successfully held its 2024 Annual Meeting, electing two directors and ratifying Ernst & Young LLP as its independent auditor.

Myriad Genetics has agreed to a settlement in a shareholder derivative lawsuit, which includes the implementation of several corporate governance reforms and a payment of up to $950,000 for legal fees.

Myriad Genetics announced a 12% year-over-year revenue increase in the first quarter of 2024, driven by growth in prenatal, pharmacogenomics, and hereditary cancer testing.

Myriad Genetics announced an 11% year-over-year revenue increase for both the fourth quarter and full-year 2023, alongside a raised revenue guidance for 2024.

Myriad Genetics reaffirmed its fiscal year 2023 revenue and non-GAAP guidance, projecting positive adjusted operating cash flow in Q4 2023, and provided preliminary Q4 2023 financial results.